Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Archer

Showing results (41-50 of 200) with videos related to

Pageof 20
Sort By:
Journal of Clinical Medicine|August 12, 2022
Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An OverviewDavid F Archer, Diana Mansour, Jean-Michel Foidart
Contraception|December 13, 2006
Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe)Steven T Nakajima, David F Archer, Herman Ellman
Fertility and Sterility|June 12, 2003
Effect of raloxifene, 17beta-estradiol, and progesterone on mRNA for vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 in Ishikawa cellsFrancisco J Navarro, Sebastian Mirkin, David F Archer
Expert Opinion on Pharmacotherapy|July 22, 2015
Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery systemIntira Sriprasert, Frank Z Stanczyk, David F Archer
Menopause (New York, N.Y.)|January 13, 2004
Effect of tibolone and its metabolites on vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 mRNA in Ishikawa cellsSebastian Mirkin, Mary C Mahony, David F Archer
Fertility and Sterility|August 9, 2005
Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cellsSebastian Mirkin, Benjamin C Wong, David F Archer
Contraception|September 28, 2015
Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptiveSteven T Nakajima, Jennifer Pappadakis, David F Archer
Expert Review of Clinical Pharmacology|July 9, 2019
A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopauseDavid F Archer, Brian A Bernick, Sebastian Mirkin
Contraception|August 2, 2015
Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerabilityDavid F Archer, Hans-Joachim Ahrendt, Dominique Drouin
Menopause (New York, N.Y.)|May 17, 2017
Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial dataDavid F Archer, Corrado Altomare, Wei Jiang, et al.
Pageof 20

Showing results (41-50 of 200) with videos related to

Sort By:
Pageof 20
Journal of Clinical Medicine|August 12, 2022
Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An OverviewDavid F Archer, Diana Mansour, Jean-Michel Foidart
Contraception|December 13, 2006
Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe)Steven T Nakajima, David F Archer, Herman Ellman
Fertility and Sterility|June 12, 2003
Effect of raloxifene, 17beta-estradiol, and progesterone on mRNA for vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 in Ishikawa cellsFrancisco J Navarro, Sebastian Mirkin, David F Archer
Expert Opinion on Pharmacotherapy|July 22, 2015
Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery systemIntira Sriprasert, Frank Z Stanczyk, David F Archer
Menopause (New York, N.Y.)|January 13, 2004
Effect of tibolone and its metabolites on vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 mRNA in Ishikawa cellsSebastian Mirkin, Mary C Mahony, David F Archer
Fertility and Sterility|August 9, 2005
Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cellsSebastian Mirkin, Benjamin C Wong, David F Archer
Contraception|September 28, 2015
Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptiveSteven T Nakajima, Jennifer Pappadakis, David F Archer
Expert Review of Clinical Pharmacology|July 9, 2019
A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopauseDavid F Archer, Brian A Bernick, Sebastian Mirkin
Contraception|August 2, 2015
Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerabilityDavid F Archer, Hans-Joachim Ahrendt, Dominique Drouin
Menopause (New York, N.Y.)|May 17, 2017
Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial dataDavid F Archer, Corrado Altomare, Wei Jiang, et al.
Pageof 20